Hygeia Healthcare Holdings Co., Ltd. (6078) AI Stock Analysis

• Market Cap: HK$10.35B
• Dividend Yield: N/A
• Average Volume (3M): 5.02M
• Price to Earnings (P/E): 15.9
• Beta (1Y): 1.63
• Revenue Growth: 7.28%
• EPS Growth: -13.77%
• Country: HK
• Employees: 8,169
• Sector: Healthcare
• Sector Strength: 55
• Industry: Medical - Care Facilities
• EPS (TTM): 1.03
• Shares Outstanding: 618,499,000
• 10 Day Avg. Volume: 5,917,260
• 30 Day Avg. Volume: 5,020,769
• PEG Ratio: -0.85
• Price to Book (P/B): 1.38
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 442.45
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$22.96
• Price Target Upside: 38.48% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 66 Neutral
• Price Target: ―

Hygeia Healthcare's overall score reflects strong financial performance driven by revenue growth and profitability. However, concerns about cash flow generation and increasing debt levels slightly dampen the outlook. Technical indicators suggest neutral to bearish momentum, and while valuation appears reasonable, the lack of a dividend yield limits appeal for income-focused investors.

Hygeia Healthcare Holdings Co., Ltd. Business Overview & Revenue Model

Company Description

Hygeia Healthcare Holdings Co., Limited operates as an oncology healthcare company in the People's Republic of China. The company owns and operates private for-profit hospitals that offer oncology healthcare services, such as tumor screening and genetic diagnosis, radiotherapy, surgery, chemotherapy, immunotherapy, targeted therapy, oncology rehabilitation, nutrition, and hospice care. It also provides radiotherapy center consulting services; and licenses its SRT equipment, as well as offers maintenance and technical support services for its SRT equipment. In addition, the company provides hospital and corporate management, and supply chain services. As of December 31, 2021, it operated or managed a network of 12 oncology-focused hospitals in 9 cities in 7 Provinces in the People's Republic of China. Hygeia Healthcare Holdings Co., Limited was founded in 2009 and is headquartered in Shanghai, the People's Republic of China.

How the Company Makes Money

Hygeia Healthcare Holdings Co., Ltd. generates revenue primarily through the provision of healthcare services within its network of specialty hospitals and clinics. The key revenue streams include fees charged for diagnostic services, treatment procedures, and inpatient care. The company benefits from China's growing demand for oncology services, driven by an increasing incidence of cancer and a rising awareness of early diagnosis and treatment. Additionally, Hygeia Healthcare may engage in partnerships with medical technology providers to enhance its service offerings, although specific partnership details are null. The company's focus on cost-effective operations and expanding its hospital network further contributes to its revenue growth.

Hygeia Healthcare Holdings Co., Ltd. Financial Statement Overview

Summary

Hygeia Healthcare shows strong revenue growth and profitability, with a robust gross profit margin. However, challenges exist in cash flow generation, particularly in free cash flow and operating cash flow alignment. The balance sheet is stable with manageable leverage, but increasing debt levels could be a future concern.

Income Statement

Hygeia Healthcare demonstrated strong revenue growth and profitability. The gross profit margin was robust at 29.36% for 2024, showing effective cost management. However, net profit margin decreased slightly to 13.45%, indicating some pressure on bottom-line profitability. Revenue grew by 9.06% from 2023 to 2024, showcasing continued expansion, but the slower growth compared to previous years may warrant monitoring.

Balance Sheet

The company's balance sheet reflects a healthy equity position, with a debt-to-equity ratio of 0.42 in 2024, indicating manageable leverage. Return on equity was solid at 8.99%, though slightly down from the previous year, suggesting efficient use of equity capital. The equity ratio is healthy at 60.88%, highlighting financial stability. However, increasing total debt levels could pose future risks.

Cash Flow

Cash flow analysis reveals challenges with free cash flow generation, as free cash flow was null in 2024. The operating cash flow to net income ratio is unavailable, suggesting a need for better alignment of operating cash flows to net income. The company must focus on enhancing cash flow from operations to support ongoing investments and debt obligations.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
4.45B	4.08B	3.20B	2.32B	1.40B
	Gross Profit
1.31B	1.29B	1.02B	744.66M	471.96M
	EBIT
821.14M	889.10M	735.77M	525.61M	318.13M
	EBITDA
999.10M	1.11B	868.43M	623.67M	385.36M
	Net Income Common Stockholders
598.26M	682.93M	476.78M	441.46M	170.09M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
651.59M	768.00M	884.71M	1.10B	2.58B
	Total Assets
10.93B	10.73B	7.24B	6.69B	4.70B
	Total Debt
2.79B	2.72B	1.29B	1.23B	2.48M
	Net Debt
2.42B	2.16B	435.35M	524.59M	-382.62M
	Total Liabilities
4.25B	4.48B	2.30B	2.21B	359.93M
	Stockholders Equity
6.65B	6.23B	4.93B	4.46B	4.27B
Cash Flow		Free Cash Flow
0.00	-157.98M	92.26M	-236.84M	-25.77M
	Operating Cash Flow
0.00	782.84M	685.38M	426.25M	296.13M
	Investing Cash Flow
0.00	-2.86B	-372.06M	-850.85M	-2.48B
	Financing Cash Flow
0.00	1.78B	-154.21M	754.50M	2.17B

Hygeia Healthcare Holdings Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 16.58
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6078, the sentiment is Positive. The current price of 16.58 is above the 20-day moving average (MA) of 15.57, above the 50-day MA of 14.79, and above the 200-day MA of 15.97, indicating a bullish trend. The MACD of 0.48 indicates Negative momentum. The RSI at 61.60 is Neutral, neither overbought nor oversold. The STOCH value of 85.40 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6078.

Hygeia Healthcare Holdings Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
6078	66 Neutral	HK$10.35B	15.89	9.30%	―	7.28%	-13.77%
Sector *	54 Neutral	$5.38B	3.31	-45.11%	3.29%	16.82%	0.04%
CYYHF		$552.17M	20.02	1.44%	0.91%	―	―
SBMFF		$10.87B	46.27	6.14%	1.22%	―	―
PANHF		$2.02B	90.39	0.96%	―	―	―
SHTDF		$7.57B	6.95	9.19%	5.61%	―	―
2WI		€23.17M	―	-151.78%	―	―	―

Hygeia Healthcare Holdings Co., Ltd. Corporate Events

Hygeia Healthcare Announces Leadership Changes

Hygeia Healthcare Holdings Co., Ltd. announced a change in its executive leadership with Ms. Cheng Huanhuan stepping down as Co-chief Executive Officer to focus on her role as an executive Director and secretary to the Board. Mr. Ren Ai has been appointed as the new Co-chief Executive Officer, bringing over 15 years of management experience from multinational corporations. This leadership change is expected to enhance the company’s operational management and strategic focus, particularly in investment, financing, and supply chain management.

Hygeia Healthcare Announces Board Structure and Roles

Hygeia Healthcare Holdings Co., Ltd. has announced the composition of its board of directors and their respective roles within the company. This announcement outlines the leadership structure, which includes both executive and independent non-executive directors, and specifies their roles in various board committees, potentially impacting the company’s governance and strategic direction.

Hygeia Healthcare Reports Revenue Growth Amidst Profit Decline

Hygeia Healthcare Holdings Co., Ltd. reported a 9.1% increase in revenue to RMB4,446.1 million for the year ending December 31, 2024, despite a 12.6% drop in net profit to RMB598.3 million. The company also repurchased over 11 million shares, with plans to cancel the remaining shares, and opted not to declare a final dividend for the year. The release highlights the use of non-IFRS measures to provide a clearer view of financial performance, although these measures have limitations and are not standardized across companies.

Hygeia Healthcare to Present 2024 Annual Results

Hygeia Healthcare Holdings Co., Ltd. announced that it will hold a conference call on March 28, 2025, to present its 2024 annual results and business operations. This initiative aims to provide shareholders and potential investors with a comprehensive understanding of the company’s financial performance and operational strategies. The presentation will be accessible online, ensuring equal and timely access to information for all stakeholders.

Hygeia Healthcare to Review Annual Results and Dividend Proposal

Hygeia Healthcare Holdings Co., Ltd. has announced that its board of directors will convene on March 27, 2025, to review and approve the company’s annual results for the year ending December 31, 2024. The meeting will also consider the recommendation of a final dividend, which could impact the company’s financial strategy and stakeholder returns.